Meeting
2017 ASCO Annual Meeting
Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.
Authors
Peter Schmid
Barts Cancer Institute, London, United Kingdom
Peter Schmid , Yeon Hee Park , Eva Muñoz-Couselo , Sung-Bae Kim , Joohyuk Sohn , Seock-Ah Im , Esther Holgado , Yang Wang , Thao Dang , Gursel Aktan , Javier Cortés
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Local-Regional Therapy
Clinical Trial Registration Number
NCT02622074
Citation
J Clin Oncol 35, 2017 (suppl; abstr 556)
DOI
10.1200/JCO.2017.35.15_suppl.556
Abstract #
556
Poster Bd #
156
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).
First Author: Charles E. Geyer Jr.
Poster
2014 ASCO Annual Meeting
Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC).
First Author: Gunter Von Minckwitz
Poster
2023 ASCO Annual Meeting
Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study.
First Author: Jeremy Meyer Force
Poster
2016 ASCO Annual Meeting
Safety and initial clinical efficacy of a dendritic cell (DC) vaccine in locally advanced, triple-negative breast cancer (TNBC) patients (pts).
First Author: Joyce O'Shaughnessy